Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

WuXi PharmaTech to Build $100 Million R&D Center in Wuhan

publication date: Aug 11, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech will spend $100 million to build a new R&D facility in the central China city of Wuhan. The company will construct a 40,000 sq meter CRO facility in the Wuhan National Biological Industry Base (Optics Valley of BioLake). Wuhan sources told ChinaBio® that a cooperative agreement between WuXi and the Wuhan Biological Base was signed on August 9. More details....

Stock Symbol: (NYSE: WX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...